A coalition of 31 Members of Parliament in the UK is voicing strong opposition to Health Secretary Wes Streeting's recent decision to grant himself the power to dictate NHS drug prices. This move has raised alarms regarding the independence of the National Institute for Health and Care Excellence (NICE), which has served since 1999 as a critical arbiter of cost-effectiveness in NHS medicine purchases. Critics, including Labour ex-shadow chancellor John McDonnell, argue that the changes represent a 'power grab' that could allow US pharmaceutical companies to influence UK drug policies significantly. The opposition is further bolstered by concerns from health experts, who warn that increased spending on drugs could necessitate cuts to other vital NHS services. The Health Foundation think tank has highlighted that rising drug costs could lead to difficult trade-offs in NHS funding, potentially harming patient care. In defense of the new regulations, the government claims the changes will enhance patient access to innovative treatments while maintaining NICE's independence. However, the Association of the British Pharmaceutical Industry (ABPI) has stated that the government's role is to set operational parameters for NICE without compromising its decision-making autonomy.